Summary. Experimental and clinical work over the last 6 years has confirmed and broadened, but also challenged, the incretin concept. The nervous component of the entero-insular axis is still poorly defined, especially the peptidergic nerves, of which several contain insulinotropic regulatory peptides. The incretin effect is preserved after complete denervation of the porcine pancreas. Type 2 (non insulin-dependent) diabetic patients have a significantly decreased incretin effect. GIP (gastric inhibitory polypeptide; glucose dependent insulin releasing peptide) remains the strongest incretin factor. Its secretion depends on the absorption of nutrients. However, the correlation between the GIP response and disturbances of the entero-insular axis in some gastrointestinal diseases and, in particular, Type 2 diabetes, is poor. Furthermore, physiological concentrations of exogenous GIP do not produce fully the incretin effect and injection of GIP antibodies does not abolish the incretin effect. This suggests the existence of additional humoral incretin factors. On the other hand, GIP seems to have direct metabolic effects independent of its insulinotropic activity. The incretin effect of oral glucose is smaller if plasma levels of C-peptide rather than insulin are measured. However, decreased hepatic extraction of insulin after glucose ingestion only accounts partially for the incretin effect. GIP is unlikely to be the gut factor which regulates hepatic insulin extraction.
More than 6 years have passed since a Claude Bernard Lecture on the incretin concept was published in this journal [1] . Since then many publications related to this subject have appeared. Many have confirmed what was known, some have broadened the concept and some have challenged it. Most investigators agree that important problems are still unsolved, such as the role of the nervous component of the entero-insular axis, especially the peptidergic nerves, and the significance of the entero-insular axis in the pathogenesis of certain diseases [2] . The difficulty of establishing a correlation between the plasma levels of recognized humoral incretin factors and disturbances of the entero-insular axis has raised the question whether other, as yet unknown, incretin factors exist.
Terminology
The term "incretin" introduced by Zunz and LaBarre in 1929 [3] to describe a humoral activity of the gut that might enhance the endocrine secretion of the pancreas (i. e. insulin), is used in this article only for hormonal stimuli of insulin secretion deriving from the gut. Such a factor should be released by nutrients, especially glucose. The difference between the insulin response after oral and that after a similar glucose load given intravenously is called the incretin effect.
The incretin concept deals with all factors responsible for the higher plasma insulin levels occurring after glucose ingestion as compared to the plasma insulin levels achieved after isoglycemic intravenous glucose infusion. It comes close to the term "entero-insular axis", coined in 1969 by Unger and Eisentraut [4] , which comprises all stimuli from the small intestine influencing the islets of Langerhans, including hormonal, neuronal and direct substrate stimulation of insulin, glucagon, somatostatin and pancreatic polypeptide [1] . Recently, much has been learned about the intestinal and nervous regulation of glucagon, somatostatin and pancreatic polypeptide secretion. In addition, there has been much speculation about intra-insular actions (paracrine, or via the islet capillaries) of these peptides on insulin secretion. However, this complex interplay will not be discussed in this review. 
Nerves and neuropeptides
For more than 50 years it has been known that vagal stimulation enhances and sympathetic nervous stimulation reduces insulin secretion ter ingestion of nutrients might augment insulin output, either via cephalic or via gastro-pancreatic and enteropancreatic vago-vagal reflexes, irrespective of the levels of insulinotropic gut hormones. The cephalic phase of insulin secretion is well documented in dogs [7] , rats [8, 9] and man [10, 11] . In man, the relative contribution of cephalic insulin secretion is still controversial [12, 13] .
Whether denervation of the pancreas impairs glucose tolerance and reduces the incretin effect has been investigated in several species, by comparing the incretin effect before and after ectopic pancreas transplantation. The data are controversial [14] [15] [16] . This may be due partially to organ damage and/or the immunosuppressive treatment given. In a recent study [17] , we demonstrated that total denervation of the pancreas in the pig (achieved by extirpation and orthotopic re-implantation) did not alter glucose tolerance and the incretin effect of a glucose load applied via a gastric tube, i.e. by-passing the cephalic phase of insulin release (Fig. 1) .
At present, it is unknown whether stimulating cholinergic and inhibiting adrenergic nerves produce a direct effect on the pancreatic islets or whether they only activate intrinsic pancreatic peptiderigic nerves which in turn influence insulin output after ingestion of nutrients. Several [27] [28] [29] , somatostatin [30] , substance P [18, 27, 31] and galanin [32] .
The peptidergic nervous system, as well as adrenergic and cholinergic nerves, may also regulate the release of duodenal factors with incretin activity. For instance, the secretion of the insulinotropic hormone, GIP, is under vagal [33] and adrenergic control [34] .
New data on GIP
GIP has remained the strongest incretin candidate. New data have accumulated to support its role as an insulinotropic factor. The insulinotropic activity of natural porcine GIP is closely related to the N-terminal residues, the amino acids in position i (tyrosine) and 2 (alanine). The previously available GIP preparations contained, in addition, a minor fraction of GIP, consisting of GIP3.42. This component displays no insulinotropic action [35, 36] . On the other hand, synthetic GIP, corresponding to the sequence 1-38 of porcine GIP, has full insulinotropic activity [37] , thereby demonstrating that amino-acids 39-42 are not necessary for this biological effect. Recently GIP has also been isolated from human [38] and bovine [39] intestine. The human form differs from the porcine in two positions and from the bovine in one position. By using specific monoclonal GIP antibodies and an immune gold technique, a single type of cell, showing round homogenous osmophile granules with a closely applied membrane and a mean size of 188 rim, has been identified as the GIP cell [40] .
Dependency of GIP secretion on nutrient absorption
Knowledge on the mechanism of the dependency of GIP release on absorption has been extended. It is known that a prerequisite for GIP release by monosaccharides is the active transport of the monosaccharide into the cell and/or its intracellular metabolism. Certain monosaccharides, which are not actively transported, such as mannose, or not metabolized, such as 2-deoxyglucose, do not stimulate GIP secretion [2, 41, 42] .
Acarbose, an a-glucosidase inhibitor, was found to drastically curtail the insulin and GIP response in man to a liquid test meal or an oral sucrose load [43] . Osmoreceptors probably do not trigger GIP output, since hyperosmolaric solutions of mannitol were not capable of increasing plasma concentrations of GIP [44, 45] . Dependency of GIP release on absorption of sugars may be one safeguard protecting the body against potential hypoglycaemia [1] . Ingestion of fat (corn oil) produces a large rise in the concentration of GIP [46, 48] , which often lasts more than 4 h. In contrast to oral glucose, the fat-induced GIP increment is not associated with a concomitant rise in plasma insulin because, as another possible safeguard against hypoglycaemia, under normo- glycaemic conditions, GIP does not exert an insulinotropic effect [49] . An increase in GIP levels only follows intraduodenal infusion of long-chain, but not medium-chain triglycerides [50] [51] [52] . Since long-chain triglycerides are transported by chylomicrons, whereas medium-chain triglycerides are directly absorbed, fat-induced GIP secretion might, to some extent, be coupled with chylomicron formation. Evidence for this contention was provided recently by experiments with Pluronic L-81 [50] , an agent which does not impair triglyceride absorption, but blocks the formation of chylomicrons within gut cells [53] . Under these conditions (e. g. completely blocked chylomicron formation) the GIP response to intraduodenal fat in rats was completely abolished (Fig. 2) .
Feedback control between GIP and insulin
A negative feedback ][oop between GIP and insulin secretion has been proposed [46] , because the fat-induced increment in plasma GIP is markedly attenuated by the simultaneous intravenous infusion of glucose [47, 54, 551 and insulin [46, 561. The GIP increment after oral glucose could not be prevented by endogenous [49] or exogenous insulin [561. Furthermore, rat C-peptide, so Glucagon Glucagon* {50 pg/ml) GIP (500 ~/mt) C~ucagon* 81ucagon* Insulin Insulin * (25mUll) GIP Fig.3 . Effect of porcine GIP on hepatic glucose output from the isolated perfused rat liver. The livers were perfused with a glucose concentration of 8.9 mmol/1 in the presence of glucagon (50 pg/ml), glucagon and GIP (500 pg/ml), glucagon and insulin (25 mU/1) and glucagon, GIP and insulin in combination. The increment in hepatic glucose output due to glucagon was calculated as Ixmol glucose, g-I liver wet weight, min -1. Perfusions were performed over 45 min. Each bar represents 11 experiments. * p< 0.005 versus glucagon alone. **p < 0.005 versus glucagon plus insulin far believed to be a biologically inactive substance, completely abolished the GIP response to intraduodenal triglyceride in rats [57] . The fact that fat-induced GIP release is under the control of insulin/C-peptide, whereas the glucose-induced GIP secretion is not, has given rise to the following speculations. Teleologically, it could be argued that the organism needs protection against an insulin-releasing agent only in the normoglycaemic state, e.g. after oral fat, but not after oral glucose. This finding may also indicate that GIP-producing cells in the gut have separate glucose and fat receptors and that only the fat receptor responds to insulin. Under hyperglycaemic clamp conditions, the GIP response to oral fat was found to be suppressed and, during a hypoglycaemic clamp, it was enhanced [58] . From these results it has been concluded that the fat-induced GIP response is not controlled by the insulin levels, but rather by the arterial blood glucose level. However, it has been demonstrated that preceding hyperinsulinaemia, as produced in these clamp studies, prevents the suppression of the GIP response by insulin and thereby masks the negative feedback inhibition of fat-induced GIP release by insulin [59] .
Direct metabolic effects of GIP
Most of the metabolic effects of GIP can be explained by its insulinotropic action. However, additional metabolic effects have been described in the absence of insulin. In isolated rat fat cells, GIP strongly inhibited the lipolytic action of glucagon. Simultaneously, the glucagon-induced increase of cyclic AMP was also blocked by GIP [60, 61] . Recent data indicate that GIP also exerts an effect on hepatic glucose production. In dogs with chronic portal venous catheters, GIP reduced hepatic glucose output without a concomitant increase in plasma insulin [62] . In the isolated perfused rat liver, even pharmacological doses of GIP were unable to inhibit the glycogenolytic effect of glucagon. However, in the presence of small amounts of insulin (25 mU/1) physiological concentrations of GIP reduced the glucagon-induced hepatic glucose output in a dose dependent manner (Fig. 3) [63] .
The fat-induced GIP release, which, in the normoglycaemic state, has no effect on insulin secretion, may be directly related to effects of GIP on fat metabolism. Thus, GIP stimulates lipoprotein lipase activity in cultured pre-adipocytes [64] . By this mechanism, triglyceride uptake would be accelerated. In dogs, infusion of GIP in concentrations which mimick the response to an oral fat load, significantly lowered the triglyceride levels attained during simultaneous chylomicron infusion [65] . This effect seems to be restricted to the removal of chylomicron triglycerides, since GIP had no effect on the removal of an intravenously infused triacylglycerol emulsion [66] . If an effect of GIP on chylomicron disposal can be confirmed, the coupling of GIP secretion to chylomicron formation during triglyceride absorption is biologically comprehensive and may become of clinical significance [50] .
Pathology of GIP secretion
One factor in the pathogenesis of the well established hyperinsulinaemia of obesity may be an overactive enteroinsular axis. An exaggerated release of GIP has been observed, together with increased insulin secretion, in obese subjects after ingestion of a high caloric liquid test meal (1031 kcal) or a large oral fat load (100 g triglycerides) but not, however, after a 100-g glucose load [67] .
The hypersecretion of GIP in obesity after nutrient ingestion has been confirmed [68] [69] [70] , while other workers found similar or even smaller post-cibal GIP responses in obesity compared with lean healthy subjects [71] [72] [73] [74] .
These discrepant results may, in part, be due to the different test meals used (solid or liquid; different calories and volumes). It is unlikely that the different antibodies used are the reason for these conflicting results. The amount of GIP released depends on the amount of food entering the duodenum. A more rapid gastric emptying rate as seen in duodenal ulcer patients [75, 76] and after gastric surgery [77] [78] [79] would explain an exaggerated GIP secretion.
In accordance with this assumption, we observed in obese subjects, the augmented GIP release only after the ingestion of 550ml of a high caloric test meal (1031 kcal) but not, however, if only 225 ml of the test meal was consumed (Fig. 4) . Obviously, the stomach of obese, but not of normal, subjects responds to a high Fig.4 . Plasma GIP levels in 10 normal subjects and 10 obese subjects after ingestion of 550 (O---(3) and 225 (H) ml of a high caloric liquid mixed test meal. 550 rnl contain 1031 and 225 m1420 kcal. * p<0.05 or less versus the 225 ml meal volume liquid meal by an increased gastric emptying rate leading to an exaggerated GIP response. In all investigations in which GIP response in obesity was normal, the test meal composition had a much lower caloric density and/or a smaller volume or consisted only of glucose.
In well-controlled Type 1 (insulin-dependent) diabetes, GIP secretion is not altered. In Type 2 diabetes, hypersecretion of GIP has been demonstrated following oral glucose or a test meal [80] [81] [82] [83] [84] . In two recent studies, a diminished response of GIP to either oral glucose [69] or a solid/liquid meal [74] was described. In the study of Elahi et al. [69] , the GIP response after glucose ingestion was exaggerated, but due to very high basal GIP levels, the relative change from basal was smaller than in controis. We studied a large group of Type 2 diabetic patients (n= 141) and found both hyper-and hyposecretion of GIP [2] (Fig. 5) . Scattergrams of the data revealed a bimodal distribution with a large group having GIP hypersecretion and a smaller group with GIP hyposecretion. No correlation existed between GIP and insulin response when both groups were analyzed. These resuits do not support the view that in certain Type 2 diabetic patients impaired glucose tolerance is causally related to diminished GIP secretion. The reason for the low GIP response in some Type 2 diabetic subjects is not known. However, it should be considered that treatment (starvation, diabetic diet, insulin therapy) may greatly influence the GIP response in these patients. Cataland and O'Dorisio [85] demonstrated that prior diet composition may have an important effect on postprandial GIP release. Consumption of natural food with 30% sucrose in normal man markedly augmented the subsequent GIP response to sucrose compared with the same subjects placed on a wheat starch-containing isocaloric diet. 
Quantification of incretin
The incretin effect, first studied by Perley and Kipnis [86] , is defined as the ratio between the integrated insulin response to an oral[ glucose load and to an isoglycaemic intravenous glucose infusion. These authors found . Integrated incremental responses of immunoreactive insulin and C-peptide to oral glucose (50 g/400 ml) (shaded columns) and respective isoglycaemic intravenous glucose infusions (white columns) are shown for 14 Type 2 diabetic patients and eight age-and weightmatched metabolically healthy subjects. Integration was carried out over 180 min. Data are given as mean+ SEM. *p<0.05: significant differences (Student's t-test) to respective values after the oral glucose load. Incretin effects are estimated by relating the difference between integrated incremental responses to oral and isoglycaemic intravenous glucose loads to the response after the oral load (= 100%) no major change in the incretin effect in patients with impaired glucose tolerance. We have tried to correlate the incretin effect with the GIP response obtained in Type 2 diabetic patients and observed that the incretin effect was markedly diminished while the GIP output was not [2] . This could be also confirmed and extended by estimating the C-peptide response (Fig. 6 ). In this recent investigation, subjects with GIP hyper-, normoand hyposecretion were included. However, no correlation existed between incretin effect and GIP response. One reason for the discrepancy between GIP response and incretin effect might be that the insulinotropic peptide GIP is unable to stimulate insulin secretion in diabetes due to a defect of the pancreatic B cells. In this context, it is of interest that Type 2 diabetic patients do not respond with sufficient insulin secretion to intravenous injection of impure cholecystokinin (CCK) [87] or porcine GIP [88, 89] , while the insulin response to intravenous secretin is intact. Alternatively, the decreased incretin effect in Type 2 diabetic patients could be caused by a defective neural transmission or the lack of incretins other than GIP, thereby explaining the reduced activity of the entero-insular axis.
Lauritsen et al. [72, 76, 90] investigated the incretin effect in several gastrointestinal conditions. In coeliac disease during remission, i.e. after improved glucose absorption, the incretin effect of 50 g glucose was normal despite a markedly reduced GIP response [90] . A similar discrepancy between the incretin effect of oral glucose and the GIP response was seen after jejunoileal bypass operation [72] . In duodenal ulcer patients, however, an increased incretin effect and augmented plasma GIP levels correlated closely [76] . The authors concluded from their results that incretins other than GIP may exist, and that these incretins are located in the distal intestine.
Evidence for the existence of additional insulinotropic factors
Some investigators have presented data which cast doubt on the unique role of GIP as the only incretin. Sarson et al. [91] compared the insulin response after a 50-g oral glucose load with that occurring after a combined intravenous infusion of glucose and GIP in providing doses similar to the oral load. They observed that, in normal subjects, the intravenous infusion of GIP and glucose produced an insulin response which was only 40% of that occurring after oral glucose. They concluded that additional insulinotropic gut factors, including neural modulation, might participate in the higher insulin response after oral glucose. In another study [92] , it was demonstrated that the concentration of exogenous GIP and of intravenous glucose required to produce significant potentiation of the insulin response appears to be in the pharmacological, rather than the physiological, range.
The physiological significance of GIP has also been examined by neutralizing endogenous GIP by means of an antibody injection in rats. The insulin response to oral glucose was only partially reduced by injection of GIP antiserum in rats [93] . In these experiments not more than 20% of the total incretin effect could be related to GIP. In control experiments GIP antiserum was able to antagonize completely the effect of exogenous GIP on insulin release. In contrast to this result, Lauritsen et al. [94] produced a complete blockade of the incretin effect in rats after pretreatment with GIP antibody. This discrepancy was probably caused by the fact that the antibody used in the latter study was raised against crude GIP and, therefore, may have neutralized additional, as yet unknown, insulinotropic gut factors. Gut extracts from which GIP was removed by immunoabsorption [53] released about 50% less insulin than GIP-containing preparations, thereby demonstrating that a significant part of the incretin effect is due to gut factors other than GIP. However, it has to be remembered that such gut extracts also contain neuropeptides with insulin-releasing potency, like VIP or PHI. Levin et al. [96] demonstrated incretin effects in a perfused rat gut-pancreas preparation after intraduodenal instillation of electrolyte solutions or mannitol. In man, inges-tion of mannitol has also been shown to augment glucose-induced insulin output [97] . These effects are certainly not due to GIP release, since mannitol or hyperosmolar electrolyte solutions are not capable of releasing GIP [45] . The authors have also demonstrated that the insulinotropic effect of mannitol only became significant if hyperosmolar solutions were tested. They concluded that increased distension of the upper gut releases a nutrient-independent incretin which may condition the islets prior to nutrient absorption [97] . Analysis of these factors has not yet been performed. Furthermore, the insulin-releasing gut factors described by Zermatten and Felber [98] and Moody [99] other than GIP have not yet been characterized.
Increased secretion or decreased hepatic extraction of insulin?
Elevated serum levels of insulin do not necessarily prove an increased rate of insulin secretion. Changes in the rate of hepatic insulin extraction during nutrient ingestion would have the same result. Insulin is extracted by more than 50% during a single hepatic passage [100] . Therefore, any alteration of the hepatic extraction rate can alter significantly plasma insulin levels and thereby alter the incretin effect. C-peptide, unlike insulin, is not degraded by the liver [101, 102] . Hence, the estimation of C-peptide gives a better measure of changes in the insulin secretion rate. On these grounds, recent investigations have claimed that the role of incretin(s) for the augmentation of insulin secretion has been greatly overestimated [103, 104] , and it has been proposed that a major part of the incretin effect is due to decreased hepatic insulin extraction. In addition, the existence of a special gut factor has been suggested which may regulate this process [105] . The nature of this factor is unknown; exogenous GIP was without effect in changing insulin or C-peptide extraction in dogs [106] . The intraportal infusion of cholecystokinin (CCK), however, diminished the insulin degradation rate [107] . It is certainly advisable to re-evaluate some of the incretin work and to estimate insulin and C-peptide simultaneously in future studies on the incretin effect. On the other hand, caution is required in the interpretation of the C-peptide: insulin molar ratio because the assumptions made in these calculations have not yet been proven [102] . 
